APA (7th ed.) Citation

T, H., T, A., T, U., R, H., H, T., & T, K. (2026). A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report. Cureus, 18(4), e107260. https://doi.org/10.7759/cureus.107260

Chicago Style (17th ed.) Citation

T, Higashi, Araya T, Ueda T, Hara R, Takato H, and Kita T. "A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report." Cureus 18, no. 4 (2026): e107260. https://doi.org/10.7759/cureus.107260.

MLA (9th ed.) Citation

T, Higashi, et al. "A Durable Response to Low-Dose Afatinib After Progression on Osimertinib in Advanced Epidermal Growth Factor Receptor (EGFR) L861Q-Mutated Lung Adenocarcinoma: A Case Report." Cureus, vol. 18, no. 4, 2026, p. e107260, https://doi.org/10.7759/cureus.107260.